First reported case of delayed‐type hypersensitivity reaction to non‐hyaluronic acid Polycaprolactone dermal filler following COVID‐19 vaccination: A case report and a review of the literature

Self Cite

With dermatologic side effects being fairly prevalent following vaccination against COVID‐19, and the multitude of studies aiming to report and analyze these adverse events, the need for an extensive investigation on previous studies seemed urgent, in order to provide a thorough body of information about these post‐COVID‐19 immunization mucocutaneous reactions. To achieve this goal, a comprehensive electronic search was performed through the international databases including Medline (PubMed), Scopus, Cochrane, Web of science, and Google scholar on July 12, 2021, and all articles regarding mucocutaneous manifestations and considerations after COVID‐19 vaccine administration were retrieved using the following keywords: COVID‐19 vaccine, dermatology considerations and mucocutaneous manifestations. A total of 917 records were retrieved and a final number of 180 articles were included in data extraction. Mild, moderate, severe and potentially life‐threatening adverse events have been reported following immunization with COVID vaccines, through case reports, case series, observational studies, randomized clinical trials, and further recommendations and consensus position papers regarding vaccination. In this systematic review, we categorized these results in detail into five elaborate tables, making what we believe to be an extensively informative, unprecedented set of data on this topic. Based on our findings, in the viewpoint of the pros and cons of vaccination, mucocutaneous adverse events were mostly non‐significant, self‐limiting reactions, and for the more uncommon moderate to severe reactions, guidelines and consensus position papers could be of great importance to provide those at higher risks and those with specific worries of flare‐ups or inefficient immunization, with sufficient recommendations to safely schedule their vaccine doses, or avoid vaccination if they have the discussed contra‐indications.

Section: Precautions For Anaphylaxis 23mentioning

confidence: 99%

A systematic review on mucocutaneous presentations after COVID‐19 vaccination and expert recommendations about vaccination of important immune‐mediated dermatologic disorders

Seirafianpour

Pourriyahi

Mesgarha

et al. 2022

Self Cite

“…Moreover, it may be a new‐onset cutaneous disorder or occur as an exacerbation of a pre‐existing dermatosis. 7 , 8 , 9 …”

Section: Introductionmentioning

confidence: 99%

“…This feature can be the first presenting symptom of the infection, may appear during the course of the disease, or even appear after the acute phase and recovery. Moreover, it may be a new‐onset cutaneous disorder or occur as an exacerbation of a pre‐existing dermatosis 7–9 …”

Section: Introductionmentioning

confidence: 99%

The role of SARS‐CoV‐2 infection and its vaccines in various types of hair loss

Aryanian

Balighi

Hatami

et al. 2022

Self Cite

The prevalence of hair loss has increased during COVID‐19. In this study, we review the current literature on incidence and characteristics of various types of COVID‐19‐related and COVID‐19‐vaccine‐ related hair loss including telogen effluvium, alopecia areata, friction alopecia and anagen effluvium. Regarding most of them, the more severe the infection, the more profound and prolonged the course of alopecia. However, the most important issue is reassuring the patients of the non‐serious nature of this complication, since psychological support is the most important factor in the earlier resolution of the condition.

“…Among them, local injection site reactions, urticarial eruptions and maculopapular rash have occurred with the highest frequency, most of which have been self-limited. [2][3][4][5][6][7] New-onset and exacerbation of some dermatological disorders, including lichen planus and psoriasis, have been reported following COVID-19 vaccination. 8 Psoriasis is a common chronic inflammatory dermatosis which can affect the skin, nails, and the axial and peripheral joints.…”

Section: Introductionmentioning

confidence: 99%

“…Vaccination against the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has been followed by several local and systemic cutaneous adverse events. Among them, local injection site reactions, urticarial eruptions and maculopapular rash have occurred with the highest frequency, most of which have been self‐limited 2–7 . New‐onset and exacerbation of some dermatological disorders, including lichen planus and psoriasis, have been reported following COVID‐19 vaccination 8 …”

Section: Introductionmentioning

confidence: 99%

SARS‐CoV‐2 vaccination and practical points in psoriasis patients: A narrative review

Aryanian

Balighi

Hatami

et al. 2022

Self Cite

SARS-CoV2 vaccines were approved without long-term monitoring due to emergent situations. This has raised some issues about timing and protocol of receiving vaccines in specific situations including patients with chronic inflammatory disorders such as psoriasis. Here, we present different aspects of SARS-CoV-2 infection and vaccination in psoriasis patients and aim to provide solutions to overcome the potential challenges. In brief, the benefits of vaccination outweigh the potential risk; vaccine-triggered de novo or flares of psoriasis is uncommon. As such, all psoriasis patients, especially those receiving systemic treatments including anti tumor necrosis factor agents, are strongly recommended to get SARS-CoV-2 vaccines. It is recommended that new immunosuppressive/immunomodulatory therapies be initiated at least 1 week after the second SARS-CoV-2 vaccine dose, if possible. In addition, in severe and active forms of psoriasis, it is better to delay vaccination until stabilization of the disease.